Novo Nordisk: oral drug cuts blood sugar in Japanese people
(CercleFinance.com) - Novo Nordisk's orally administered semaglutide has demonstrated greater reductions in both blood glucose (HbA1c) and body weight compared to Victoza and placebo in Japanese people with type-2 diabetes, the Danish company said.
A phase 3 trial achieved its primary endpoint by demonstrating that people treated with 3, 7 and 14 mg of oral semaglutide experienced statistically significant reductions in HbA1c of 1.1%, 1.5% and 1.7%, respectively, compared to a 0.1% reduction with placebo after 26 weeks, Novo said.
After 52 weeks, people treated with 3, 7 and 14 mg orally administered semaglutide experienced respective reductions of 0.9%, 1.3% and 1.5% in HbA1c, compared to an increase of 0.5% for people treated with placebo.
The trial compared orally administered semaglutide with Novo's Victoza and with placebo in 243 Japanese adults with type-2 diabetes.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A phase 3 trial achieved its primary endpoint by demonstrating that people treated with 3, 7 and 14 mg of oral semaglutide experienced statistically significant reductions in HbA1c of 1.1%, 1.5% and 1.7%, respectively, compared to a 0.1% reduction with placebo after 26 weeks, Novo said.
After 52 weeks, people treated with 3, 7 and 14 mg orally administered semaglutide experienced respective reductions of 0.9%, 1.3% and 1.5% in HbA1c, compared to an increase of 0.5% for people treated with placebo.
The trial compared orally administered semaglutide with Novo's Victoza and with placebo in 243 Japanese adults with type-2 diabetes.
Copyright (c) 2018 CercleFinance.com. All rights reserved.